-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ifetroban in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ifetroban in Duchenne Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ifetroban in Duchenne Muscular Dystrophy Drug Details: Ifetroban (Vasculan, Boxaban, Hepatoren,Portaban)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Prexasertib Mesylate Monohydrate in Recurrent Medulloblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Prexasertib Mesylate Monohydrate in Recurrent Medulloblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prexasertib Mesylate Monohydrate in Recurrent Medulloblastoma Drug Details: Prexasertib (LY-2606368...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Prexasertib Mesylate Monohydrate in Refractory Medulloblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Prexasertib Mesylate Monohydrate in Refractory Medulloblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prexasertib Mesylate Monohydrate in Refractory Medulloblastoma Drug Details: Prexasertib (LY-2606368...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Prexasertib Mesylate Monohydrate in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Prexasertib Mesylate Monohydrate in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prexasertib Mesylate Monohydrate in Endometrial Cancer Drug Details: Prexasertib (LY-2606368...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Prexasertib Mesylate Monohydrate in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Prexasertib Mesylate Monohydrate in Metastatic Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prexasertib Mesylate Monohydrate in Metastatic Ovarian Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niraparib in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Niraparib in Malignant Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Niraparib in Malignant Mesothelioma Drug Details: Niraparib (MK-4827, Zejula) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Diakine-DK210 (EGFR) in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Diakine-DK210 (EGFR) in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diakine-DK210 (EGFR) in Non-Small Cell Lung Cancer Drug...
-
Product Insights
Medulloblastoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Medulloblastoma - Drugs In Development, 2023’, provides an overview of the Medulloblastoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Medulloblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...